TILRAY IN AUSTRALIA
Tilray is playing an active role in the development of Australia's medicinal cannabis industry through clinical research partnerships, compassionate access programs, and plans for commercial operations.
Australia has some of the world's most forward-thinking researchers in the field of clinical research on cannabinoids. Tilray is excited to collaborate with them to advance our scientific understanding of the benefits and risks of cannabis as medicine.
In February 2016, Tilray joined the Government of New South Wales, University of Sydney, and Chris O'Brien Lifehouse to announce a groundbreaking clinical trial that will examine the safety and efficacy of a Tilray study drug for the treatment and nausea and vomiting caused by chemotherapy (CINV). The study drug will be developed and produced by Tilray in Canada, then exported from Canada to Australia for the trial.
The trial marks the first time a well-defined, orally-administered, cannabis-derived medicine will be studied in patients with chemotherapy-induced nausea. With more than 300 patients at several sites throughout New South Wales expected to participate, this will be one of the largest clinical trials studying cannabis ever to be conducted anywhere in the world.
In the coming months, Tilray will announce additional research partnerships in Australia.
Thank you for your interest in Tilray, a global leader in pharmaceutical-grade medical cannabis products. If you are looking for further information on how to access the special access scheme through the TGA, please review the following guidelines for Category B patients: https://www.tga.gov.au/form/special-access-scheme
For further information on Tilray, please have your physician contact: firstname.lastname@example.org
In addition to supporting clinical research and compassionate access for patients in Australia, Tilray hopes to invest AU$15-20 million to establish commercial operations in the country, employing up to 100 local staff, pending implementation of the federal government’s cultivation and processing regulations later this year.
IN THE NEWS
February 25, 2016: Tilray, New South Wales Government, University of Sydney and the Chris O’Brien Lifehouse Announce Clinical Trial Partnership for Cannabinoid Use to Combat Nausea and Vomiting Resulting from Chemotherapy Treatment
TO LEARN MORE ABOUT PARTNERING WITH TILRAY IN AUSTRALIA:
Director of Business Development